We suggest that MetAP1 expression could be routinely checked in several types of tumor, as a prognostic marker for predicting the efficacy of any treatments targeting MetAP2 activity and for the fine-tuning of therapeutic strategies. The gene discussed is METAP1; the disease is neoplasm.